Cargando…
Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV(+) “low-risk” locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study
BACKGROUND: Human papillomavirus-associated oropharyngeal cancer (HPV-OSCC) is rapidly increasing in incidence and has unique epidemiologic, molecular, and biologic characteristics. Standard combined modality therapies for head and neck cancer confer a significant risk of morbidity. However, patient...
Autores principales: | Economopoulou, Panagiota, Psyrri, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460733/ https://www.ncbi.nlm.nih.gov/pubmed/31093366 http://dx.doi.org/10.1186/s41199-019-0040-5 |
Ejemplares similares
-
De-Escalating Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma
por: Economopoulou, Panagiota, et al.
Publicado: (2021) -
Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial
por: Jones, David A., et al.
Publicado: (2020) -
Special Issue about Head and Neck Cancers: HPV Positive Cancers
por: Economopoulou, Panagiota, et al.
Publicado: (2020) -
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
por: Mehanna, Hisham, et al.
Publicado: (2019) -
HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study
por: Economopoulou, Panagiota, et al.
Publicado: (2019)